shrna feb 2013
TRANSCRIPT
Sample & Assay Technologies- 1 -
SureSilencing™ shRNA Plasmids
Knock Down Your Favorite Genes with Ease and Confidence with shRNA
Wei Cao, [email protected]
.Technical Support:
.Tel: 1-888-503-3187
.Email: [email protected]
.International customers: [email protected]
.Webinar related questions: [email protected]
Sample & Assay Technologies- 2 -
Online Seminar @ QIAGEN- A great way to learn new technologies
http://sabioscience.com/seminarlist.php
Sample & Assay Technologies- 3 -
Topics will be Covered
RNAi Introduction and Challenges1
2 Solutions: SureSilencing shRNA Plasmid
Key Points to Ensure Successful RNAi3
Application Examples 4
Topic II (Today):
Topic I:RNAi High Throughput Screening Applications, Challenges and Solutions; April 5, 1pm Eastern Time
https://www2.gotomeeting.com/register/772647330
Sample & Assay Technologies- 4 -
RNA Interference Introduction
What are siRNAs?siRNAs are 21–23nt (nucleotide) dsRNA duplexes with symmetric 2–3nt 3' overhangs and 5'-phosphate and 3'-hydroxyl groups
How does it work?Dicer delivers the siRNAs to a group of proteins called the RISC (RNA-Inducing Silencing Complex)
siRNA duplex unwinds
Once unwound, the single-stranded antisense strand guides RISC to mRNA that has a complementary sequence
Sample & Assay Technologies- 5 -
RNAi Strategies: shRNA & siRNA
siRNA shRNAOrigin Synthetic oligonucleotides Plasmids or vector basedBiogenesis Introduced into cell by
transfectionSynthesized in cell; enters RNAi pathway
Gene silencing effect
Transient Non-transient, long term effect
Effect on protein production
Decrease protein levels Decrease protein levels
Applications
Quick transient knockdown, not for long term knocking down; not for enrichment
Transient or stable transfection;Build stable cell lines for renewable source of gene knockdown;Transfer shRNA between different vectors;Inheritable silencing.
� The choice of which one to use, depends on the question under investigation, and factors such as cell type, time demand, and the need for transient or stable knockdown.
QIAGEN’s Solution
Flexitube, Flexiplate siRNA SureSilencing shRNA Plasmids
Sample & Assay Technologies- 6 -
Why Knockdown the Expression of a Gene?
RNAi
Target Identification and Validation
Pathway Interrogation
Biomarker and Drug Target Discovery
Gene Function Studies
Sample & Assay Technologies- 7 -
RNAi Challenges
� RNAi Knockdown Effectiveness
� Differences exist between: Knockdown efficiencies advertised by
companies & observed by researchers
� RNAi Specificity, Off-Target effect (OTE)
1. Sequence-specific OTEs
� Mismatches between the siRNA guide strand and the complementary target
mRNA sequence, ‘seed region’
� siRNAs function like microRNAs
2. Non-sequence-specific OTEs
� Lipid-mediated response - cellular response to RNAi toxicity
� Immune responses to RNAi, such as induction of Interferon pathway
� RISC-dependent off-target effects
Sample & Assay Technologies- 8 -
Solutions @ QIAGEN
SureSilencing shRNA Plasmids
Sample & Assay Technologies- 9 -
SureSilencing shRNA Plasmids
� Guaranteed >70% Knockdown for Every Human, Mouse, and Rat Gene
� Power discovered by thousands of scientists worldwide
� More than 200 publications in a broad range of research fields.
� Cancer� Stem Cell � Immunology � Neuroscience � Signal Transduction� Cell Differentiation � Cardiovascular Disease� Infectious Diseases (HIV, HCV)
�Check website: http://www.sabiosciences.com/support_publication.php
�Customer’s success story: http://www.sabiosciences.com/RNAipublication.php
Sample & Assay Technologies- 10 -
SureSilencing shRNA – How it works
� A vector is introduced into cells and utilizes the U1 promoter to ensure that the shRNA is always expressed.
� Dicer cleaves the shRNA into siRNA.
� The siRNA gene silencing mechanism is followed.
shRNAPlasmid
Sample & Assay Technologies- 11 -
SureSilencing shRNA Plasmids – Mechanism
FACS enrichment Antibiotic-resistance markers: Stable Cell Line Dev elopment
GFP
shRNAPlasmid
U1 promoterExpression
Amp:Propagation
Cell Selection
Enrich or Select: 4 Markers: GFP, Nyomycin, Hygromycin, and Puromycin;Multiple Designs: 4 Designs for each gene – each sequence targets different region
Hyg PuroNeo
Sample & Assay Technologies- 12 -
The Best shRNA Design Algorithm
Download White Paper “Did Your RNAi Experiment Work?!”http://www.sabiosciences.com/validaternai.pdf
Sample & Assay Technologies- 13 -
The Best RNAi Design Algorithm
� Ensure Efficacy: Filter many chemical & sequence properties of siRNA known to be important for activity
� Length, between 19bps ~ 30bps
� GC Content, between 32%~55%� Thermostability bias at 5’-end of antisense strand� Avoid tandem repeats and palindromes:
• no internal repeated sequences of length >=4;
• no GC stretch of length >=8;• no repeats of AAA, UUU, GGG or CCC; • no internal palindrome sequences of length >=5;
� Ensure Specificity with Smith-Waterman sequence alignment algorithm, “Better than BLAST”
� Experimentally Validated shRNA Plasmids� 2 of 4 successful designs per gene IS an Enforceabl e Guarantee!
Zhou H, Zeng X, Wang Y and Seyfarth BR. A Three-Phase Algorithm for Computer Aided siRNA Design.
Informatica.2006 30:357-364.
Sample & Assay Technologies- 14 -
Validation of SureSilencing shRNAs
� Experimental Validation of shRNA Plasmids
� 329 Designs tested, 221 are successful: 67.2 % (>2/3);
� 86 Genes tested, 74 are successful: 86.0 % (>4/5);
� Original publication by The RNAi Consortium (TRC) reports only 31-38 % (~1/3) success rate using the same definition of success
Designs Tested
Successful Designs
Success Rate (%)
Genes Tested
Successful Genes
Success Rate (%)
SABio’s Set 329 221 67.2 86 74 86.0
The RNAi Consortium
2561, 5422 971, 172 381, 312 53 40 75.5
1. RootRoot DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM. “Genome-scale loss-of-function screening with a lentiviral
RNAi library.” Nat Methods. 2006 Sep;3(9):715-9.
2. Moffat J, Grueneberg DA, Yang X, et. al. “A lentiviral RNAi library for human and mouse genes applied to an arrayed viral
high-content screen.” Cell. 2006 Mar 24;124(6):1283-98.
Sample & Assay Technologies- 15 -
SureSilencing shRNA plasmids- benefits
� Guaranteed >70% gene knockdown efficiency
� Control Off-target effects by multiple shRNA plasmids� Offer 4 shRNA plasmid designs for each gene� Experimentally validated shRNA design algorithm
� Track/ Enrich or Select� Use Neomycin, Puromycin and Hygromycin markers to build stable cell lines and
study long term effects of gene suppression.� Use GFP Marker to track and enrich transfected cells and study short term effects of
gene suppression.
� Convenient and Cost-Effective� Use standard plasmid-based and lipid-mediated transfection methods � Plasmids provide a renewable source of RNA Interference.
� Accepted by thousands of scientists in various rese arch fields
Sample & Assay Technologies- 16 -
� Search by Gene
� Search by pathway
or disease
SureSilencing shRNA plasmids – search portal
Genome-wide collection of human, mouse and rat gene s.http://sabiosciences.com/shRNA.php
Sample & Assay Technologies- 17 -
SureSilencing shRNA plasmids – search portal
� Search by pathway or diseases
Sample & Assay Technologies- 18 -
SureSilencing shRNA plasmids - contents
� Kit Contents:• 4 SureSilencing shRNA Plasmids - transformation grade• One Negative Control - a scrambled artificial sequence• Sequences are provided
� Additional Material Required:
• Transformation: Competent E. coli cells & other reagents for transformation (LB, ampicillin, plates)
• Plasmid Purification: Plasmid purification kit, such as EndoFree Plasmid Maxi Kit (QIAGEN Cat# 12362) and QIAfilter Plasmid Midi Kit (QIAGEN Cat# 12243)
• Transfection: Lipid-mediated transfection reagent (Attractene QIAGEN Cat#301004, or others) or electroporator; Antibiotics: Hygromycin, G418 (for Neomycin), or Puromycin
• Real-time PCR Verification of knockdown: • cDNA synthesis kit (Cat# 330401)• RT2 SYBR Green Master Mix (Cat# 330500)• RT2 Primer Assays – target gene of interest and a housekeeping gene
Sample & Assay Technologies- 19 -
Workflow for shRNA plasmids knockdown
Start with shRNA Plasmids
3 Steps
1
23
24 or 48 Incubation
GFP enrich < 1 day
Select with antibiotic ~1-2 week
Sample & Assay Technologies- 20 -
Workflow for shRNA plasmids knockdown
Assay effects of gene knockdown� mRNA level
• Real time qPCR, Northern blot, end-point PCR
� Protein level• SDS-PAGE and Western Verification
• Other Biochemical Assays • Timing is critical (when do I look, when do I do experiment)
RT2 PCR Validation of gene knockdown at mRNA level• cDNA synthesis kit, RT2 SYBR Green Master Mix
• Primers for target gene and housekeeping (control) gene such as ACTB and GAPD
• Template from transfected cells with target gene shRNA and negative control shRNA
• Perform PCR reaction
• Data Analysis
Sample & Assay Technologies- 21 -
Control shRNATarget shRNA
Target Gene
Control shRNA Target shRNA
Housekeeping Gene
Real-Time PCR Validation of shRNA Knockdown
� Target gene expression decreases by 2 threshold cycles, indicating >70% knockdown;
� Housekeeping gene expression is not altered upon transfection with the target gene shRNA plasmid relative to the control shRNA.
Sample & Assay Technologies- 22 -
shRNA experiment optimization
� Controls
� Enrichment
� Selection
� Validation
Key points to ensure successful RNAi
Sample & Assay Technologies- 23 -
Optimization #1 - controls
� Untreated cells: Use normal cells in a normal culture condition as a pure background
� Mock control: For transfection reagent (transient experiment only). Cells treated with transfection reagent only without any shRNA plasmid DNA. Help to identify any effect directly from the transfection reagent
� Non-targeting shRNA control: Use the same shRNA expression vector that will activate RISC and the RNAi pathway, but does not target any human, mouse or rat genes. This allows for examination of the effects of shRNA transfection and RNAi activation on gene expression. Cells transfected with the non-target shRNA vector will also provide a useful reference for interpretation of knockdown.
This negative control is provided with each shRNA p lasmid set
Sample & Assay Technologies- 24 -
Percent Knockdown
Pre-Sorted Population (%)Knockdown
Sorted Population(%) Knockdown
PRKCAProtein Kinase C alpha
37 71.8 (69.7, 73.8)
TP53Tumor protein p53
52 70.8 (68.4, 73.0)
FACS-based enrichment for GFP-expressing cells
� Transient transfection may have lower efficiency in some cell lines; � Unsorted cells may exhibit lower knockdown due to a large population of untransfected
cells; � Sorting will remove the untransfected cells and enrich the population, thus providing a
true measurement of knockdown;� Peak Ex. of the GFP at 505nm, with a shoulder at 480nm; Em. occurs at 515nm
Optimization #2 - enrichment
Sample & Assay Technologies- 25 -
Potential challenge when using pooled population� Initial stably antibiotic selected whole pool population appears to
fail, due to: -Random integration sites affect shRNA expression and knockdown efficiency-Average knockdown efficiency of all integration sites is seen, some better than others
� Strategy: Clone stably transfected cells with two best designs, then select by limiting dilution- Leading a high success rate: 2 out of 5 tested now successful
Optimization #3 - selection
Antibiotic selection strategy � Before transfection, determine “effective concentration” of
antibiotics-depends on cell line, growth rate, state of confluence
� After transfection, re-plate cells at a low cell density (≤10%) and grow cells in medium containing the effective concentration of antibiotic
Selection using entire pool
Individual Stably Selected Clones
Sample & Assay Technologies- 26 -
Optimization #4 - validation
To ensure >70% knockdown efficiency:• Transfection Efficiency (TE): >=80%• Biological Sample Consistency: 3
Validation – qPCR at the mRNA level• PCR Reproducibility• PCR Amplification Efficiency• Site-specific primer may be
necessary for some genes
Validation – at protein levelAt protein level, knockdown is not always immediately apparent
• Need to optimize timing• Protein level measurement – Western blot, enzyme activity assay, reporter assay, etc.
0
10
20
30
40
50
60
70
80
90
100
A B C D E
Designs
Kno
ckin
g do
wn
effic
ienc
y (%
)
default primer
site specific primer
Sample & Assay Technologies- 27 -
Application Examples – Case Studies
shRNA Case Studies
Sample & Assay Technologies- 28 -
shRNA Case Study 1
� Validation of STAT3 RNAi Design in-house
Target GOI (Gene of interest): STAT3 (Signal transducer and activator of transcription 3)
Cell model: 293H cells
Assay method: Real-time RT-PCR
Control HKG (Housekeeping gene): ACTB (Beta actin)
Sample & Assay Technologies- 29 -
shRNA Case Study #1– Experimental Workflow
shRN
A1
shRN
A3
shRN
A2
shRN
A4
TransfectionGrade shRNAs
Cell Culture:293H cells were cultured in D-MEM with 10% FBS and 1x non-essential amino acids for no more than 15 passages.
shRNA Delivery:Mix 4 STAT3 shRNA plasmids (GFP) (0.8mg) with 3mL Lipofectamine 2000 reagent in a 24-well plate; Change culture media after 24hr transfection.
Checked transfection efficiency by GFP expression using fluorescence microscopy
Isolate total RNA:Isolated total RNA after 48 hrs
3 x 4 GOI+ 3 x 1NC = 15
� Validation of STAT3 RNAi Design
Isolate RNA
Sample & Assay Technologies- 30 -
shRNA Case Study #1– Experimental Workflow
Reverse Transcription:Synthesized cDNA from total RNA (15 samples)
Primer set and Master Mix cocktail:2 cocktails: GOI and HKGCocktail = cDNA + Master mix + H2O
Set up & perform real-time PCR:3 technical replicatesGOI: 15 x 3 =45HKG: 15 x 3 =45
Analyze data:Free data analysis template performs all the calculation & generate report http://www.sabiosciences.com/rnaidataanalysis.php Analyze data & report
Total RNA->cDNA� Validation of STAT3 RNAi Design
15 samples
Sample & Assay Technologies- 31 -
shRNA Case Study #1– Data Analysis & Report
DATE11/3/2011
Transfection 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
STAT3 PCR 1 24.00 24.11 24.08 24.44 24.18 24.18 31.54 22.67 23.09 24.31 24.51 24.26 28.96 23.03 22.90STAT3 PCR 2 24.09 24.30 24.29 24.56 24.31 24.32 31.58 22.78 23.33 24.46 24.55 24.35 28.83 22.94 22.82
STAT3 PCR 3 24.02 24.28 24.19 24.57 24.32 24.28 31.92 22.82 23.28 24.47 24.64 24.29 28.87 23.00 22.83
Average Ct 24.04 24.23 24.19 24.52 24.27 24.26 31.68 22.76 23.23 24.41 24.57 24.30 28.89 22.99 22.85
SD Ct 0.05 0.10 0.11 0.07 0.08 0.07 0.21 0.08 0.13 0.09 0.07 0.05 0.07 0.05 0.04
QC 1 OK OK OK OK OK OK OK OK OK OK OK OK OK OK OKACTB PCR 1 17.65 17.74 17.62 17.79 17.82 17.81 26.38 18.03 18.46 17.85 17.87 17.68 25.05 19.18 19.15
ACTB PCR 2 17.83 17.96 17.70 17.86 17.87 17.74 26.39 17.93 18.50 17.86 17.94 17.81 24.90 19.10 19.12ACTB PCR 3 17.72 17.81 17.66 17.77 17.75 17.83 26.45 18.00 18.32 17.69 17.84 17.63 24.97 19.15 19.16
Average Ct 17.73 17.84 17.66 17.81 17.81 17.79 26.41 17.99 18.43 17.80 17.88 17.71 24.97 19.14 19.14
SD Ct 0.09 0.11 0.04 0.05 0.06 0.05 0.04 0.05 0.09 0.10 0.05 0.09 0.08 0.04 0.02
QC 2 OK OK OK OK OK OK OK OK OK OK OK OK OK OK OK
∆Ct 6.30 6.39 6.53 6.72 6.46 6.47 5.27 4.77 4.81 6.61 6.68 6.59 3.91 3.85 3.71
SD ∆Ct 0.10 0.15 0.11 0.09 0.10 0.09 0.21 0.09 0.16 0.13 0.08 0.10 0.10 0.06 0.05
Average ∆Ct
SD ∆Ct BIO
Overall Mean SD ∆Ct
∆∆Ct
Overall SD ∆∆Ct
QC 3Percent of Control
Percent Knock Down+ SD- SD
Report:STAT3-1 ( 80.88 85.48 )STAT3-2 ( 82.39 87.00 )STAT3-3 ( 41.33 64.31 )STAT3-4 ( 84.09 87.18 )
0.28
3.82
0.11
0.11
2.59
0.18
6.55
0.16
0.15
2.72
0.19
6.41
0.13
0.11
OK
1.13
0.32
6.63
0.08
0.05
2.81
0.14
4.95
0.30
1.30
1.43
83.341.91
2.15
84.871.90
2.17
STAT3-4 Negative ControlReal-Time PCR Result for STAT3 shRNA
54.24 85.720.17 0.15 0.46 0.14
OK
95 % Confidence Interval83.3484.87
STAT3-1 STAT3-2 STAT3-3
9.02
11.24
OK OK
54.2485.72
DesignSuccessfulSuccessfulMediocre
Successful
Percent Knock Down
GOI- STAT3
HKG - ACTB
Sample & Assay Technologies- 32 -
shRNA Case Study #2
� Case Study 2 – Published by customers
Sample & Assay Technologies- 33 -
shRNA Case Study #2 – Cancer Research
� Study: The role of PELP1/MNAR signaling in Ovarian Tumorig enesis
PELP1/MNAR (Proline-, glutamic acid–, and leucine–rich protein-1): a NR coregulator
� An example using GFP marker to monitor transfection efficiency and screen the
best design, then using selection marker for long t erm knockdown study.
Method:• Model: OVCAR3 cells expressing PELP1/MNAR-shRNA; • Initially used transient transfection assay to screen 4 shRNA plasmids with GFP, and
80-90% transfection efficiency was monitored by GFP expression after 24 hrs;• Transfected OVCAR3 cells with 5 ug negative control shRNA or 2 PELP1/MNAR-
shRNA plasmids with Neomysin;• Selected transfected cells using G418 (1mg/ml) for long term knockdown;• Assayed the knockdown effect of PELP1/MNAR using Western blot after 72 hrs
Sample & Assay Technologies- 34 -
shRNA Case Study 2 – Cancer Research
• PELP1 expression is ~100% blocked in OVCAR3 by Western blotting; PR, cyclin D1 were down-regulated;• The colonies of PELP1/MNAR/shRNA decreased analyzed by soft agar colony formation assay;• The expression of Src, AKT and MAPK were decreased by down-regulation of PELP1, by Western analysis of total protein lysates with phospho-specific antibodies
Conclusion: PELP1/MNAR plays a critical role in the proliferation of ovarian cancer cells.
OVCAR3OVCAR3
~100% knockdown of PELP1 expression in OVCAR3 cells
Sample & Assay Technologies- 35 -
SureSilencing shRNA Plasmids - Benefits
� Efficiency and Specificity: Guaranteed success (> 70% gene knockdown by 2 different shRNA plasmids) & Minimized off-target effects
� Flexibility: 4 markers, GFP, Neomycin, Hygromycin, Puromycin, allow for transient and long-term selections
� Convenient & Cost-effective: Use standard plasmid-based and lipid-mediated transfection methods. Plasmids provide a renewable shRNA resource of RNAi
� Genome Wide RNAi tool for Human, Mouse and Rat genes
� Search portal: Easy to search your gene of interest.
Search by gene or by Pathway or Diseasehttp://www.sabiosciences.com/RNAisearch.phphttp://www.Qiagen.com
Sample & Assay Technologies- 36 -
SureSilencing shRNAs for Every Gene- A complete system for RNAi from QIAGEN
shRNAs Transfection Purification Analysis
Attractene
� High efficiency and low cytotoxicity for DNA transfection
� Suitable for all adherent cells and sensitive cells
� Ideal for co-transfection and vector-based RNAi (shRNA)
� Free of animal-derived components
RNeasy Kit
� Fast and high-quality total RNA in minutes
� Consistent RNA yields from small amounts of starting material
� No phenol/chloroform extraction, no CsCl gradients, no LiCl or ethanol precipitation
qPCR Primer assaySYBR® Green-based
� High performance: bench validated
� Complete genome coverage: human, mouse, rat, rhesus macaque, fly, etc
� Convenience: Within 5-minutes, deliver guaranteed performance
Sample & Assay Technologies- 37 -
Dicer is required in both the siRNA and miRNA pathways
What’s the phenotypic effect of Dicer knock down on p53 signaling?
Assessing RNA Interference Phenotypes- by Cignal Reporter Assay System
Conclusion: The regulation of p53 signaling is tightly controlled by
microRNA and/or siRNA processing.
Cignal Reporter Assay System
P53 Reporter
+ Dicer siRNA
■ Dual-luciferase & GFP format
■ Plasmid based reporter assay
■ Lentivirial based reporter assay
Sample & Assay Technologies- 38 -
Thank You for Attending!
20% off of your next shRNA or siRNA orders (+ a Qiagen logo digital clock)
Promo code: FDK-WN20C12
Call 888-503-3187 to order
Email: [email protected]
Search Portalhttp://sabioscience.com/RNAi.php
www.qiagen.comwww.GeneGlobe.com
SureSilencing shRNAs for Every Gene- A complete system from QIAGEN
SureSilencing shRNA Plasmids� available for EVERY human, mouse, and rat gene
� per gene set - 4 designs and 1 control� 4 Marker Selection: GFP, Neomycin, Puromycin and Hygromycin